Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential

Dec 30, 2024Cureus

Resmetirom for Treating Fatty Liver Disease Linked to Metabolic Problems: Review of Current Evidence and Potential Benefits

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Resmetirom is a recently FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH).

Resmetirom is associated with the reduction of intra-hepatic lipids and improvement in liver tissue health.
Key outcomes show that resmetirom may lead to resolution of non-alcoholic steatohepatitis (NASH) and improvement in fibrosis in a significant percentage of patients.
Common gastrointestinal side effects are noted, but the drug maintains a favorable safety profile.
Ongoing phase 3 trials aim to provide essential information on the long-term efficacy and safety of resmetirom.

AI simplified

Resmetirom is a thyroid hormone receptor agonist that has been recently approved by the FDA for the management of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a severe form of metabolic dysfunction-associated fatty liver disease (MASLD), which is marked by hepatic inflammation and potential progression to cirrhosis and liver cancer. This review analyzes and demonstrates the efficacy of resmetirom in reducing intra-hepatic lipids, improving liver histology, and improving metabolic parameters. Key outcomes of this study indicate that resmetirom leads to non-alcoholic steatohepatitis (NASH) resolution and fibrosis improvement in a substantial percentage of patients. Although this drug has common gastrointestinal side effects, it maintains a favorable safety profile. With the increase in demand for treatments of MASH, the ongoing phase 3 trials will provide critical insights into the long-term efficacy and safety profile of resmetirom and further solidify its potential as a groundbreaking therapeutic option for the management of MASH.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief